北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)
作者: Zhou, Caicun; Wu, Yi Long; Liu, Xiaoqing; Wang, Changli; Chen, Gongyan; Feng, Ji Feng; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Cheng-ping; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu
刊名: JOURNAL OF CLINICAL ONCOLOGY
发表日期: 2012-05-20
卷: suppl.S, 期:15
收录类别: SCI ; ISTP
文章类型: Meeting Abstract
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
语种: 英语
WOS记录号: WOS:000318009804317
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/66429
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Jiangsu Prov Canc Hosp, Nanjing, Jiangsu, Peoples R China
2.Peking Univ, Canc Hosp, Beijing 100871, Peoples R China
3.Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
4.Harbin Med Univ, Affiliated Hosp 3, Harbin, Peoples R China
5.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
6.Acad Mil Med Sci, Ctr Canc, Hosp 307, Beijing, Peoples R China
7.Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
8.Capital Med Univ, Bejiing Chest Hosp, Beijing, Peoples R China
9.Jiao Tong Univ, Shanghai Chest Hosp, Shanghai 200030, Peoples R China
10.Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
11.Shanghai Jiao Tong Univ, Renjin Hosp, Shanghai 200030, Peoples R China
12.Capital Med Univ, Beijing Lung Canc Ctr, Beijing, Peoples R China
13.Second Mil Med Univ, Changzheng Hosp, Shanghai, Peoples R China
14.Cent S Univ, Xiang Ya Hosp, Changsha, Hunan, Peoples R China
15.Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China
16.Shantou Univ, Coll Med, Canc Hosp, Shantou, Peoples R China
17.Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
18.Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China

Recommended Citation:
Zhou, Caicun,Wu, Yi Long,Liu, Xiaoqing,et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)[J]. JOURNAL OF CLINICAL ONCOLOGY,2012,suppl.S(15).
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhou, Caicun]'s Articles
[Wu, Yi Long]'s Articles
[Liu, Xiaoqing]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhou, Caicun]‘s Articles
[Wu, Yi Long]‘s Articles
[Liu, Xiaoqing]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace